GSK has agreed to acquire Nuvalent in a $10.6 billion (£8.0 billion) transaction, a major expansion of its oncology pipeline. The deal adds a Boston-based clinical-stage biopharmaceutical developer focused on targeted cancer therapies and is likely to be viewed as strategically positive for GSK's long-term growth profile.
GSK has agreed to acquire Nuvalent in a $10.6 billion (£8.0 billion) transaction, a major expansion of its oncology pipeline. The deal adds a Boston-based clinical-stage biopharmaceutical developer focused on targeted cancer therapies and is likely to be viewed as strategically positive for GSK's long-term growth profile.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.72
Ticker Sentiment
